Ashwagandha
Ashwagandha scored 6.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Adaptogen / Herbal → Adaptogenic Herb.
Ashwagandha is a useful adaptogen for stress, anxiety, and sleep: Fatima 2024 found lower HAM-A anxiety scores across 5 RCTs, while Arumugam 2024 found reduced stress, anxiety, and cortisol. Main caveats are industry-heavy trials, liver injury reports, thyroid stimulation, pregnancy avoidance, and mood blunting.
What is Ashwagandha?
Ashwagandha, also known as Withania somnifera, is an adaptogenic supplement used for stress resilience, anxiety, sleep, and selected hormone or performance goals. The strongest human case is stress physiology: Chandrasekhar 2012 and Salve 2019 both support lower stress and cortisol-linked outcomes, and newer reviews such as Fatima 2024 and Arumugam 2024 keep the stress, anxiety, and sleep signal alive in the current literature.
Mechanistically, ashwagandha is not one molecule doing one thing. Withanolides, withaferin A, alkaloids, and sleep-related constituents appear to influence the HPA axis, GABA, inflammatory signaling, antioxidant-response pathways, and endocrine feedback loops. That explains why the benefits spread across stress, sleep, testosterone, thyroid, cognition, VO2max, and strength outcomes without any one endpoint looking drug-like. Bonilla 2021 supports physical-performance benefits, while Zhu 2026 extends the modern review base into cognition and physical function.
The catch is that ashwagandha is not a harmless wellness powder. LiverTox now lists it as a likely cause of clinically apparent liver injury, Björnsson 2020 documents a liver-injury case series, Sharma 2018 shows thyroid stimulation that can be useful in subclinical hypothyroidism but risky in hyperthyroidism, and LactMed 2024 reports inadequate lactation safety data. Ashwagandha earns a 7.0 because it works for the right stressed person, not because everyone should take it forever.
Terminology
- Withania somnifera: Botanical name for ashwagandha, a nightshade-family plant used in Ayurvedic medicine.
- Adaptogen: A broad term for herbs used to improve stress resilience. The term is useful culturally but does not replace endpoint-specific evidence.
- HPA axis: Hypothalamic-pituitary-adrenal axis, the body's central stress-response system that regulates cortisol output.
- Cortisol: A stress hormone that is useful acutely but can impair sleep, libido, body composition, and cognition when chronically elevated.
- KSM-66: Root-only ashwagandha extract, commonly standardized to 5% withanolides. Best default evidence base.
- Sensoril: Root-and-leaf ashwagandha extract, typically more sedating and more sleep-oriented than KSM-66.
- Shoden: High-concentration extract used at lower milligram doses, with a thinner trial base than KSM-66.
- Withanolides: Steroidal lactone compounds considered major active constituents in ashwagandha extracts.
- Withaferin A: A potent withanolide more concentrated in leaf material and relevant to inflammatory, antioxidant, and thyroid-related signaling.
- GABAergic: Related to GABA, the brain's main inhibitory neurotransmitter system. This helps explain ashwagandha's sleep and calming effects.
- Nrf2: A transcription factor that regulates antioxidant-response genes.
- NF-kB: A transcription factor involved in inflammatory signaling.
- HAM-A: Hamilton Anxiety Rating Scale, a clinician-rated anxiety scale used in trials and meta-analyses.
- PSS: Perceived Stress Scale, a questionnaire used to measure subjective stress.
- VO2max: A measure of maximal oxygen uptake and cardiorespiratory fitness.
- LiverTox: NIH database tracking drug, herb, and supplement liver-injury evidence.
- Rasayana: Ayurvedic category for restorative tonics used for vitality, resilience, and long-course strengthening.
How do you take Ashwagandha?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Standardized root extract | KSM-66 or comparable root-only capsule, usually 5% withanolides | 300 mg once or twice daily, typically 300-600 mg/day | 300-600 mg/day; some users exceed this, but higher doses raise sedation and mood-blunting risk |
| Root-and-leaf extract | Sensoril capsule or tablet, commonly standardized to higher withanolides plus oligosaccharides | 125-250 mg once or twice daily, often 250 mg in the evening for sleep | 125-500 mg/day, with evening dosing preferred when sedation is the goal |
| High-concentration extract | Shoden extract standardized to high withanolide glycoside concentration | 60-120 mg/day | 60-120 mg/day |
| Traditional root powder | Dried Withania somnifera root powder, often mixed with milk or warm liquid | 3-6 g/day in traditional use; modern RCT evidence uses extracts more often than powder | 1-6 g/day |
Protocols
Stress and anxiety default Clinical
- Dose
- 300 mg KSM-66 with breakfast and 300 mg with dinner
- Frequency
- Daily
- Duration
- 8 weeks, then reassess or take 2-4 weeks off
Matches common RCT duration and dose range. Best for adults with elevated perceived stress or cortisol-linked symptoms.
Sleep-onset protocol Clinical
- Dose
- 125-250 mg Sensoril or 300 mg root extract 30-60 minutes before bed
- Frequency
- Nightly
- Duration
- 4-8 weeks, then reassess
Use the lowest effective dose. Avoid stacking with alcohol, benzodiazepines, Z-drugs, or other sedatives unless supervised.
Athletic performance support Clinical
- Dose
- 300 mg KSM-66 twice daily
- Frequency
- Daily
- Duration
- 8-12 weeks during a training block
Most relevant for high-stress training blocks where cortisol reduction and recovery support are the goal. Not a stimulant.
Conservative cycling protocol Mixed
- Dose
- 300-600 mg/day standardized extract
- Frequency
- 5 days on, 2 days off, or 8 weeks on and 2-4 weeks off
- Duration
- Repeat only if benefits remain clear
Designed to reduce mood-blunting and tolerance-like user reports. Stop if emotional flatness, apathy, or reduced drive appears.
Clinician-monitored thyroid protocol Clinical
- Dose
- 300 mg root-only extract twice daily
- Frequency
- Daily
- Duration
- 8 weeks only, with labs
Only for hypothyroid-dominant or subclinical hypothyroid contexts under clinician care. Avoid completely in hyperthyroidism and Graves' disease.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of Ashwagandha?
Upside contribution: 2.70
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.8 | 0.950 | |
| Breadth | 15% | 4.5 | 0.675 | |
| Evidence | 25% | 4.0 | 1.000 | |
| Speed | 10% | 3.0 | 0.300 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality | 15% | 3.5 | 0.525 | |
| Total | 3.700 |
Upside Rationale
Ashwagandha earns a solid efficacy mark because the herb produces real, measurable change on stress, anxiety, sleep, and a few performance endpoints, not just subjective vibes. Fatima 2024 found lower HAM-A anxiety scores across five randomized trials, and Arumugam 2024 found reduced perceived stress, anxiety, and serum cortisol across nine trials. Chandrasekhar 2012 and Salve 2019 anchor the core cortisol signal, Langade 2019 supports sleep and anxiety, Wankhede 2015 supports strength and recovery, and Choudhary 2015 supports endurance. Pooled effects sit in the moderate-to-large range for an herb, enough to feel, but not enough to outrank first-line sleep, stress, or strength interventions.
Ashwagandha reaches across more body systems than almost any other single supplement because stress biology touches nearly everything downstream. Human trials on ashwagandha span perceived stress, anxiety, sleep quality, cortisol, testosterone, subclinical thyroid indices, cardiorespiratory endurance, resistance-training recovery, and cognition. Bonilla 2021 consolidates the performance evidence, Cheah 2021 consolidates the sleep evidence, and Zhu 2026 broadens cognition and physical-function coverage. The breadth is genuinely wide, which is why ashwagandha scores near the top here, though several secondary categories still rest on single trials or specific populations. Ashwagandha is broadest for stressed, under-recovered people rather than universally useful for already-optimized users.
Ashwagandha now sits on a strong evidence base because the trial pool replicates across independent meta-analyses, not just one favorable study. Akhgarjand 2022, Fatima 2024, Arumugam 2024, Ferreira 2025, and Alsanie 2026 all point the same favorable direction for mental-health and performance endpoints, reinforced by Bachour 2025 and centuries of documented Ayurvedic use. The remaining limits are real: high heterogeneity, short durations, small samples, and manufacturer-linked funding in many branded-extract studies. That industry-funding haircut keeps ashwagandha just below the top tier rather than at it. The audit also found no dedicated Cochrane conclusion, no FDA therapeutic approval, and no mainstream sleep-medicine endorsement, so ashwagandha rates strongly within the supplement evidence world without crossing into clinical-grade certainty.
Ashwagandha works faster than most classic adaptogens but slower than acute drugs, so set expectations around weeks, not hours. Calming and sleep-onset effects from ashwagandha can show up within one to two weeks, especially with the more sedating root-and-leaf extracts. Stress and cortisol outcomes generally need four to eight weeks of consistent dosing. Testosterone, thyroid-index, strength, recovery, and endurance outcomes are usually measured around the eight-week mark in the randomized trials, and full adaptogenic benefit is better judged over eight to twelve weeks. The practical rule with ashwagandha: if nothing has shifted after a clean eight-week trial at 300 to 600 mg per day, it probably is not your lever, and you should redirect effort elsewhere.
Ashwagandha benefits are supplementation-dependent, which is the main reason its durability score stays low. Stop taking ashwagandha and the sleep, anxiety, cortisol, and vitality effects typically drift back toward baseline over a few weeks. There is no evidence that ashwagandha teaches a durable skill, permanently resets the HPA axis, or creates lasting structural change after a short cycle. Cycling can preserve subjective benefit and reduce the mood-blunting that creeps in with long continuous use, but cycling also confirms that ongoing intake drives most of the effect. Treat ashwagandha as a functional tool you maintain, not a one-time intervention that fixes the underlying stress architecture and then keeps paying dividends once you walk away from it.
Ashwagandha is strongly responder-dependent, so who you are matters more here than the dose on the bottle. Strong responders to ashwagandha tend to be chronically stressed adults, poor sleepers with high arousal, men with stress-suppressed vitality, some subclinical hypothyroid patients, and athletes grinding through high-stress training blocks. Weak responders include low-stress users, people with already-low cortisol, anyone prone to sedation, and those expecting stimulant-like energy. Hyperthyroid and Graves patients, pregnant or breastfeeding users, people with liver disease, and medication-heavy users move from maybe-useful toward avoid-or-supervise. This context-dependence is why ashwagandha is not a universal foundational supplement on the level of creatine, magnesium, or protein, even though it scores well overall.
What are the risks & downsides of Ashwagandha?
Downside contribution: 1.26 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 2.5 | 0.750 | |
| Side effects | 15% | 2.3 | 0.345 | |
| Cost | 5% | 1.5 | 0.075 | |
| Effort | 5% | 1.0 | 0.050 | |
| Opportunity | 5% | 2.0 | 0.100 | |
| Dependency | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.920 | |||
| Harm subtotal × 1.4 | 2.373 | |||
| Opportunity subtotal × 1.0 | 0.225 | |||
| Combined downside | 2.598 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.258 |
Downside Rationale
Ashwagandha carries a real but uncommon safety profile that deserves measured caution rather than either alarm or a casual all-clear. LiverTox lists ashwagandha as a likely cause of clinically apparent liver injury, usually cholestatic or mixed, and Bjornsson 2020 documents five liver-injury cases drawn from Iceland and the US Drug-Induced Liver Injury Network. Thyroid stimulation is the other clinically relevant concern: Sharma 2018 shows ashwagandha improving thyroid indices in subclinical hypothyroid patients, which means it can push an already-overactive thyroid the wrong way, supported by thyroiditis case evidence. Pregnancy and breastfeeding stay firmly in the avoid column for ashwagandha because valid lactation safety data simply do not exist.
Ashwagandha side effects are generally mild and well-tolerated, which is why this dimension scores better than its old, overstated mark. Most people on ashwagandha experience nothing worse than occasional GI upset, nausea, loose stools, mild sedation, vivid dreams, headache, or next-day grogginess, and these tend to resolve with dose timing or a lower dose. The root-and-leaf extracts like Sensoril skew more sedating than root-only extracts, so extract choice matters. The one effect worth watching with ashwagandha is mood blunting, the emotional flatness or reduced drive that some users report after higher doses or long continuous use. It is underreported in trial adverse-event tables but consistent enough in real-world ashwagandha use to keep this from scoring even lower.
Ashwagandha is genuinely cheap, which keeps its financial cost low and accessible for almost anyone. KSM-66 ashwagandha typically runs $15 to $30 per month at 600 mg per day, Sensoril roughly $12 to $25, Shoden around $20 to $40, and generic root powder as little as $5 to $15. The only real cost penalty with ashwagandha is quality: the cheapest products carry higher adulteration and heavy-metal uncertainty, so anyone using it seriously should pay a small premium for third-party-tested extracts. Even at the top of that range, ashwagandha remains one of the more affordable interventions in the stress and sleep category, so price is rarely the deciding factor against trying it.
Ashwagandha asks almost nothing of your time or attention, which is part of its appeal. Most ashwagandha protocols are one to two capsules daily with food, or a single evening dose taken for sleep, and that is the entire routine. Lab monitoring adds effort only for people with a thyroid history, liver concerns, active medication interactions, or long-term high-dose use, and even then it is an occasional check rather than an ongoing chore. The bigger behavioral burden with ashwagandha is not the dosing but the discipline to stop, reassess, and cycle rather than letting a daily capsule quietly become a permanent autopilot habit you never actually evaluate.
Ashwagandha can quietly distract you from fixing the upstream causes of your stress, which is the core of its opportunity cost. If your chronic stress traces back to sleep debt, overtraining, conflict, under-eating, alcohol, no daylight, or an impossible workload, ashwagandha may make the stress response feel more tolerable while the actual source stays untouched. The cost is moderate, not severe, because ashwagandha stacks cleanly with better foundations rather than blocking them: L-theanine for acute calm, phosphatidylserine for cortisol timing, zone 2 cardio for resilience, and basic sleep hygiene for recovery. Use ashwagandha alongside the real fixes, not as a substitute for them.
Ashwagandha does not create classic physiological dependency, so withdrawal risk is low. There is no known ashwagandha withdrawal syndrome, no receptor-rebound pattern like benzodiazepines, and no documented cortisol surge after stopping. When people quit ashwagandha they usually notice a gradual return of their original stress, sleep, or vitality symptoms over two to eight weeks, which reflects loss of an active effect rather than true dependence. The only dependency worth naming with ashwagandha is behavioral: leaning on a daily capsule to tolerate a lifestyle that actually needs structural repair. That is a habit-of-mind risk, not a pharmacological one, and it is easily managed by cycling and periodic reassessment of whether ashwagandha is still earning its place.
Ashwagandha effects are largely reversible once you stop, which keeps its reversibility risk low. Sleep, stress, cortisol, testosterone, and thyroid-index changes from ashwagandha tend to drift back toward baseline after discontinuation, and the mood blunting some users report usually resolves after a dose reduction or a break. The one caveat keeping ashwagandha from the lowest possible score is that the rare liver-injury cases can take weeks to months to fully resolve, so reversibility is not instant or trivial for everyone. For the typical user, though, walking away from ashwagandha returns them close to where they started, with no lasting imprint left behind once the supplement clears the system.
Is Ashwagandha worth it?
Ashwagandha is a 6.8 / 10 fit for people using stress resilience, anxiety, and sleep quality as a measured experiment, not a belief-based staple. The best anchors are Arumugam et al. 2024, which reports nine randomized trials, 558 participants and reduced perceived stress, anxiety, and serum cortisol versus placebo, and Bachour et al. 2025, which reports conference abstract and 15 studies, 873 participants and reduced HAM-A, PSS, and cortisol at 8 weeks, with no significant quality-of-life improvement. That gives Ashwagandha a real signal, but the report should stay narrow because responder fit, baseline status, and outcome tracking drive the practical value. Use Ashwagandha when the target is specific, measurable, and worth the tradeoff. Skip or stop Ashwagandha when the expected symptom, lab, or performance marker stays flat.
✅ Best for: Chronically stressed adults with elevated perceived stress, poor sleep onset, or cortisol-linked fatigue; adults with mild anxiety who want a non-prescription adjunct rather than a replacement for therapy or indicated medication; men with stress-suppressed vitality where sleep, protein, training, and alcohol are already addressed; athletes in hard training blocks seeking modest recovery support; and subclinical hypothyroid patients only when a clinician is monitoring TSH, T3, and T4. KSM-66 at 300 to 600 mg/day is the best default. Sensoril is better for sleep-specific use. Shoden is reasonable when pill burden matters.
❌ Avoid if: You are pregnant, trying to become pregnant without clinician guidance, breastfeeding, hyperthyroid, diagnosed with Graves' disease, dealing with current or past liver disease, or allergic to nightshade-family plants. Avoid unsupervised use with thyroid medication, sedatives, alcohol-heavy routines, antihypertensives, antidiabetic medications, immunosuppressants, or multi-ingredient testosterone boosters. Also avoid ashwagandha if your real problem is a broken stress system you have no intention of changing. It may mute the signal without fixing the source.
What is Ashwagandha best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Stress / Resilience: 7.5/10
Score: 7.5/10For stress resilience, Ashwagandha earns 7.5/10 because the evidence points to a plausible use case without proving a universal response. Arumugam et al. 2024 is the best anchor here because it reports nine randomized trials, 558 participants and reduced perceived stress, anxiety, and serum cortisol versus placebo. Bachour et al. 2025 adds context, but the exact stress resilience outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Anxiety: 7.5/10
Score: 7.5/10Mechanistically, Ashwagandha scores 7.5/10 for anxiety because the evidence points to a plausible use case without proving a universal response. Arumugam et al. 2024 is the best anchor here because it reports nine randomized trials, 558 participants and reduced perceived stress, anxiety, and serum cortisol versus placebo. Bachour et al. 2025 adds context, but the exact anxiety outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Sleep Quality: 6.5/10
Score: 6.5/10The sleep quality case for Ashwagandha lands at 6.5/10 because the evidence points to a plausible use case without proving a universal response. Fatima et al. 2024 is the best anchor here because it reports five randomized trials, 254 participants and reduced HAM-A anxiety scores and improved several sleep parameters, with high heterogeneity. Salve et al. 2019 adds context, but the exact sleep quality outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Hormonal / Endocrine: 6.5/10
Score: 6.5/10Population fit explains the 6.5/10 hormonal score for Ashwagandha because the evidence points to a plausible use case without proving a universal response. Lopresti et al. 2019 is the best anchor here because it reports randomized crossover study and direction supports hormonal changes, but v0 numeric wording was tempered by audit. Fatima et al. 2024 adds context, but the exact hormonal outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Mood / Emotional Regulation: 6.0/10
Score: 6.0/10The main limitation behind Ashwagandha's 6.0/10 mood score is that the evidence points to a plausible use case without proving a universal response. Alsanie et al. 2026 is the best anchor here because it reports 22 randomized trials, 1391 participants and improvements in stress, anxiety, and depression, with dose and duration effects and low-certainty limitations. Fatima et al. 2024 adds context, but the exact mood outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Fertility (Male): 6.0/10
Score: 6.0/10For fertility male, Ashwagandha earns 6.0/10 because the evidence points to a plausible use case without proving a universal response. Lopresti et al. 2019 is the best anchor here because it reports randomized crossover study and direction supports hormonal changes, but v0 numeric wording was tempered by audit. Fatima et al. 2024 adds context, but the exact fertility male outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Libido / Sexual Health: 5.5/10
Score: 5.5/10Mechanistically, Ashwagandha scores 5.5/10 for libido because the evidence points to a plausible use case without proving a universal response. Fatima et al. 2024 is the best anchor here because it reports five randomized trials, 254 participants and reduced HAM-A anxiety scores and improved several sleep parameters, with high heterogeneity. Arumugam et al. 2024 adds context, but the exact libido outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Anti-Inflammatory: 5.5/10
Score: 5.5/10The main limitation behind Ashwagandha's 5.5/10 anti inflammatory score is that the evidence points to a plausible use case without proving a universal response. Fatima et al. 2024 is the best anchor here because it reports five randomized trials, 254 participants and reduced HAM-A anxiety scores and improved several sleep parameters, with high heterogeneity. Arumugam et al. 2024 adds context, but the exact anti inflammatory outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Cognition / Focus: 5.0/10
Score: 5.0/10For cognition focus, Ashwagandha earns 5.0/10 because the evidence points to a plausible use case without proving a universal response. Zhu et al. 2026 is the best anchor here because it reports 20 studies, 1249 participants and improved memory, attention and processing speed, executive function, and physical-function-related outcomes. Fatima et al. 2024 adds context, but the exact cognition focus outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Immune Function: 5.0/10
Score: 5.0/10The immune function case for Ashwagandha lands at 5.0/10 because the evidence points to a plausible use case without proving a universal response. Ferreira et al. 2025 is the best anchor here because it reports overview of 11 systematic reviews, 151 original studies, 9005 participants and signals for endurance, strength, anxiety, sleep, and sexual function, with caution. Zhu et al. 2026 adds context, but the exact immune function outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Muscle Growth / Hypertrophy: 5.0/10
Score: 5.0/10Population fit explains the 5.0/10 muscle growth score for Ashwagandha because the evidence points to a plausible use case without proving a universal response. Ferreira et al. 2025 is the best anchor here because it reports overview of 11 systematic reviews, 151 original studies, 9005 participants and signals for endurance, strength, anxiety, sleep, and sexual function, with caution. Wankhede et al. 2015 adds context, but the exact muscle growth outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Geriatric / Aging Population: 5.0/10
Score: 5.0/10Mechanistically, Ashwagandha scores 5.0/10 for geriatric because the evidence points to a plausible use case without proving a universal response. Fatima et al. 2024 is the best anchor here because it reports five randomized trials, 254 participants and reduced HAM-A anxiety scores and improved several sleep parameters, with high heterogeneity. Arumugam et al. 2024 adds context, but the exact geriatric outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
Strength / Power: 5.0/10
Score: 5.0/10The strength power case for Ashwagandha lands at 5.0/10 because the evidence points to a plausible use case without proving a universal response. Ferreira et al. 2025 is the best anchor here because it reports overview of 11 systematic reviews, 151 original studies, 9005 participants and signals for endurance, strength, anxiety, sleep, and sexual function, with caution. Wankhede et al. 2015 adds context, but the exact strength power outcome still needs baseline-matched tracking. That makes Ashwagandha most defensible as a short, measured trial for someone with a clear target. Track the relevant symptom, lab, or performance marker, then stop Ashwagandha if the expected change does not appear.
| Use Case | Score | Summary |
|---|---|---|
| ○ Neuroprotection | 4.5 | Neuroprotection is supported more by mechanism and cognition-adjacent outcomes than clinical neuroprotection trials. Zhu 2026 strengthens adult cognitive and physical-function evidence, but there are no dedicated human neuroprotection outcome trials proving disease modification. |
| ○ Antioxidant / Oxidative Stress | 4.5 | Antioxidant support is mechanistically credible through Nrf2 and related pathways, but human endpoint evidence is not as strong as stress evidence. Withanolide signaling can shift endogenous antioxidant defenses, yet this remains a supporting mechanism rather than a primary reason to use ashwagandha. |
| ○ Sleep Architecture (Deep/REM) | 4.5 | Sleep architecture earns a moderate score because Langade 2019 included objective sleep assessment and Cheah 2021 supports a sleep meta-analysis signal. Evidence is better than most adaptogens but not comparable to full sleep-medicine interventions. |
| ○ Endurance / Cardio | 4.5 | Endurance-cardio evidence is moderate. Choudhary 2015 supports cardiorespiratory endurance in athletic adults, and Bonilla 2021 supports physical-performance benefits. This remains a training-support supplement, not an endurance drug. |
| ○ Fertility (Female) | 4.0 | Female sexual-function data is not the same as fertility evidence. V0 preserved a modest score because direct female fertility RCT evidence is thin, and pregnancy remains an avoidance context. Ashwagandha should not be used as a conception or pregnancy supplement without medical direction. |
| ○ Longevity / Lifespan | 4.0 | Longevity remains indirect. Rasayana use in Ayurveda, stress reduction, sleep support, and inflammatory modulation all point in a healthspan-friendly direction, but there are no human lifespan trials. The practical longevity case is cortisol and sleep support in the right person, not a direct anti-aging intervention. |
| ○ Metabolic Health | 4.0 | Metabolic benefit is mostly secondary to stress reduction. Salve 2019 supports modest movement in stress-linked cardiometabolic measures, but there is no dedicated high-confidence metabolic RCT base. Additive glucose lowering with diabetes medications is a practical safety issue. |
| ○ HRV / Vagal Tone / Autonomic Balance | 4.0 | HRV and vagal-tone evidence is plausible but under-measured. Lower stress and better sleep can improve autonomic balance, but the audit did not verify a dedicated HRV-powered RCT. Treat HRV improvement as a reasonable tracking metric, not a guaranteed endpoint. |
| ○ Bone / Joint Health | 4.0 | Bone-joint support is anti-inflammatory and trial-limited. V0 preserved an osteoarthritis-like KSM-66 signal, but the audit did not re-verify all joint-specific details. Score remains moderate because the mechanism fits but the evidence is far thinner than stress, anxiety, and sleep. |
| ○ Neuroplasticity | 4.0 | Neuroplasticity is mostly preclinical and cognition-adjacent. Withanolide biology supports neuronal-growth hypotheses, and Zhu 2026 improves the adult cognition evidence base. Direct human brain-imaging or structural neuroplasticity trials remain absent. |
| ○ Cardiovascular | 3.5 | Cardiovascular benefit is indirect and modest. Stress, cortisol, sleep, inflammation, and blood-pressure endpoints can move in favorable directions in some trials, including Salve 2019. Ashwagandha is not a primary cardiovascular therapy, and medication interactions with antihypertensives matter. |
| ○ Blood Sugar / Glycemic Control | 3.5 | Blood-sugar support is modest and indirect. Cortisol reduction can improve insulin sensitivity in stressed users, and v0 evidence included glucose improvements, but ashwagandha is not a diabetes treatment. Users on antidiabetic medications should monitor for additive glucose lowering. |
| ○ Energy / Fatigue | 3.5 | Energy effects are restorative rather than stimulating. Users with poor sleep, elevated stress, or burnout-like physiology may feel more stable energy after stress improves. Low-stress users may feel sedated or blunted instead, especially with Sensoril or high doses. |
| ○ Chronic Pain Management | 3.5 | Chronic-pain support is modest. Anti-inflammatory pathways and v0 joint-pain data justify the score, but ashwagandha is not an analgesic and lacks broad pain-condition RCT depth. Consider it adjunctive only when stress or inflammation is part of the pain pattern. |
| ○ Body Composition / Fat Loss | 3.5 | Body-composition support is training-dependent. Wankhede 2015 supports resistance-training benefits, while cortisol reduction may help stressed users retain lean mass. It is not a fat-loss supplement and does little without training, protein, and sleep. |
| ○ Reaction Time / Coordination | 3.5 | Reaction-time support is modest and likely mediated by stress reduction. V0 evidence included reaction-time improvements, and Zhu 2026 supports broader processing-speed outcomes. This is not a stimulant-like acute performance lever. |
| ○ Injury Recovery | 3.5 | Injury recovery is plausible through inflammation, sleep, and training recovery, but direct injury-specific RCTs are lacking. Wankhede 2015 supports recovery-adjacent strength-training outcomes, so the score stays exploratory rather than primary. |
| ○ Skin / Beauty | 3.0 | Skin-beauty support is indirect. Stress and inflammation can worsen skin quality, and antioxidant pathways may help, but the audit found no dedicated dermatology RCT to elevate this score. Use red light therapy, sun management, protein, and sleep before ashwagandha for skin goals. |
| ○ Circadian Rhythm / Chronobiology | 3.0 | Circadian support is secondary. Better sleep and cortisol rhythm can help users feel more aligned, but ashwagandha does not directly provide a light, meal-timing, or temperature cue. Morning sunlight and consistent wake time remain stronger circadian interventions. |
Frequently Asked Questions
Is ashwagandha actually worth taking?
For the right person, yes. Fatima 2024 found lower HAM-A anxiety scores across 5 RCTs, and Arumugam 2024 found lower stress, anxiety, and cortisol across 9 RCTs. The case is strongest for chronically stressed adults and weaker for low-stress users. Main caveats: industry-heavy trials, short duration, liver injury reports, thyroid stimulation, pregnancy avoidance, and mood blunting with overuse.
What is the difference between KSM-66, Sensoril, and Shoden?
KSM-66 is the best default, Sensoril is more sleep-oriented, and Shoden is the low-dose high-concentration option. KSM-66 is root-only and has the broadest trial base, including Chandrasekhar 2012. Sensoril includes root and leaf material and tends to be more sedating. Shoden uses a much lower milligram dose but has a thinner trial base. If you have thyroid concerns, root-only extract is the more conservative starting point.
Does ashwagandha increase testosterone?
Ashwagandha can support testosterone in selected men, but it is not a replacement for testosterone therapy. Lopresti 2019 found hormonal and vitality effects in aging overweight males, and Wankhede 2015 found strength and recovery benefits during resistance training. The expected responder is stressed, sleeping poorly, or under-recovered. Men with high-normal testosterone and low stress should expect much less.
Can ashwagandha cause liver damage?
Yes, rarely. LiverTox lists ashwagandha as a likely cause of clinically apparent liver injury, usually cholestatic or mixed, with onset commonly 2 to 12 weeks after starting. Björnsson 2020 describes 5 cases from Iceland and the US Drug-Induced Liver Injury Network. Stop immediately and seek care for jaundice, dark urine, intense itching, right-upper abdominal pain, or unusual fatigue.
Does ashwagandha cause mood blunting or emotional numbness?
Yes, mood blunting is a real practical concern, especially above 600 mg/day or with continuous use beyond 8 to 12 weeks. RCTs do not measure this community signal well, but the pattern is consistent: reduced anxiety can slide into flatness, apathy, and lower drive. The conservative approach is 300-600 mg/day, 8 weeks on followed by 2-4 weeks off, and stopping quickly if emotional range or motivation drops.
Is ashwagandha safe with thyroid conditions?
Ashwagandha is potentially useful in subclinical hypothyroid contexts but risky in hyperthyroidism. Sharma 2018 found thyroid-index improvement in subclinical hypothyroid patients. Painless thyroiditis case evidence and older thyrotoxicosis reports support the caution in thyroid-overactive users. Avoid ashwagandha with hyperthyroidism or Graves' disease. If you take levothyroxine, methimazole, or propylthiouracil, involve your clinician.
How long does ashwagandha take to work?
Expect early effects in 1 to 2 weeks and fuller effects by 8 weeks. Stress and anxiety often move first, sleep usually follows within 2 to 4 weeks, and hormonal or performance endpoints usually require 8 weeks. Langade 2019 used a 10-week sleep and anxiety trial, while many stress and performance studies use 8-week windows. After stopping, benefits usually fade over weeks.
Should I cycle ashwagandha?
Cycling is the conservative default. No RCT proves the perfect cycle, but long continuous use is where mood blunting and diminished subjective benefit show up most often. A practical protocol is 8 weeks on and 2 to 4 weeks off, or 5 days on and 2 days off. Ferreira 2025 supports broad performance and psychological signals but also emphasizes evidence limitations, so long-term caution is reasonable.
What could change Ashwagandha's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Large independent NIH-scale RCT replicates stress and anxiety benefits with transparent extract testing | Evidence 3.5 to 4.5; Bioindividuality 3.5 to 4.0 | 7.1 / 10 💪 Strong recommend |
| Prospective pharmacovigilance confirms liver-injury incidence is extremely rare and consistently reversible | Safety 2.5 to 1.5 | 7.3 / 10 💪 Strong recommend |
| Prospective pharmacovigilance finds materially higher liver-injury incidence or confirmed fatality attributable to ashwagandha | Safety 2.5 to 3.5 | 6.3 / 10 👍 Worth trying |
| Head-to-head RCT shows cycling prevents mood blunting better than continuous use | Side effects 2.8 to 2.0; Evidence 3.5 to 3.8 | 6.8 / 10 👍 Worth trying |
| Thyroid-toxicity case series shows frequent severe outcomes in susceptible users | Safety 2.5 to 4.0 | 6.0 / 10 👍 Worth trying |
| FDA, AASM, or Cochrane issues a favorable indication-specific conclusion for stress or insomnia | Evidence 3.5 to 4.0 | 6.8 / 10 👍 Worth trying |
Key Evidence Sources
- Fatima et al. 2024 - Safety and efficacy of Withania somnifera for anxiety and insomnia: systematic review and meta-analysis, Human Psychopharmacology. 5 RCTs, n=254; reduced HAM-A anxiety scores and improved several sleep parameters, with high heterogeneity.
- Arumugam et al. 2024 - Effects of Ashwagandha on stress and anxiety: systematic review and meta-analysis, EXPLORE. 9 RCTs, n=558; reduced perceived stress, anxiety, and serum cortisol versus placebo.
- Bachour et al. 2025 - Effects of Ashwagandha Supplements on Cortisol, Stress, and Anxiety Levels in Adults: systematic review and meta-analysis, BJPsych Open. Conference abstract; 15 studies, n=873; reduced HAM-A, PSS, and cortisol at 8 weeks, with no significant quality-of-life improvement.
- Ferreira et al. 2025 - Biopsychological Effects of Ashwagandha in Athletes and Healthy Individuals: systematic review, Muscles. Overview of 11 systematic reviews, 151 original studies, n=9005; signals for endurance, strength, anxiety, sleep, and sexual function, with caution on evidence limits.
- Alsanie et al. 2026 - Effects of Ashwagandha on Mental Health in Adults: systematic review and dose-response meta-analysis, Complementary Therapies in Medicine. 22 RCTs, n=1391; improvements in stress, anxiety, and depression, with dose and duration effects and low-certainty limitations.
- Zhu et al. 2026 - Effects of Withania somnifera on Cognitive and Physical Function in Adults: systematic review and meta-analysis, Frontiers in Pharmacology. 20 studies, n=1249; improved memory, attention and processing speed, executive function, and physical-function-related outcomes.
- Akhgarjand et al. 2022 - Does Ashwagandha supplementation have a beneficial effect on anxiety and stress? systematic review and meta-analysis, Phytotherapy Research. Meta-analysis of RCTs; direction supports reduced stress and anxiety. Exact v0 effect sizes were not re-frozen without full-text recheck.
- Bonilla et al. 2021 - Effects of Ashwagandha on Physical Performance: systematic review and Bayesian meta-analysis, Journal of Functional Morphology and Kinesiology. Systematic review and Bayesian meta-analysis supporting physical-performance benefits.
- Lopresti et al. 2019 - Hormonal and Vitality Effects of Ashwagandha in Aging, Overweight Males, American Journal of Men's Health. Randomized crossover study; direction supports hormonal changes, but v0 numeric wording was tempered by audit.
- Choudhary et al. 2015 - Ashwagandha for cardiorespiratory endurance in healthy athletic adults, AYU. RCT in athletic adults; direction supports cardiorespiratory endurance improvement.
- Chandrasekhar et al. 2012 - High-concentration full-spectrum ashwagandha root extract for stress and anxiety, Indian Journal of Psychological Medicine. Randomized double-blind placebo-controlled stress trial; supports lower stress, anxiety, and cortisol.
- Salve et al. 2019 - Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults, Cureus. Dose-ranging RCT; supports lower perceived stress, HAM-A scores, cortisol, and improved sleep quality.
- Langade et al. 2019 - Ashwagandha root extract in insomnia and anxiety: randomized placebo-controlled study, Cureus. Sleep and anxiety RCT with objective and subjective sleep outcomes.
- Sharma et al. 2018 - Ashwagandha root extract in subclinical hypothyroid patients, Journal of Alternative and Complementary Medicine. Double-blind RCT; supports TSH, T3, and T4 normalization in subclinical hypothyroid patients.
- Wankhede et al. 2015 - Withania somnifera supplementation on muscle strength and recovery: randomized controlled trial, Journal of the International Society of Sports Nutrition. Resistance-training RCT; supports strength, recovery, and training-adaptation benefits.
- Cheah et al. 2021 - Effect of Ashwagandha extract on sleep: systematic review and meta-analysis, PLOS ONE. Sleep meta-analysis; small significant overall sleep effect, stronger in insomnia, higher-dose, and longer-duration studies.
- Björnsson et al. 2020 - Ashwagandha as a cause for liver injury, Liver International. Five liver-injury cases associated with ashwagandha use; mixed or cholestatic pattern, prolonged jaundice, resolution in reported cases.
- LiverTox 2024 - Ashwagandha, NCBI Bookshelf. NIH hepatotoxicity monograph; ashwagandha listed as likely cause of clinically apparent liver injury.
- Withania - LactMed 2024, NCBI Bookshelf. Lactation monograph; no valid safety or efficacy data for nursing mothers or infants.
- Saper et al. 2008 - Lead, Mercury, and Arsenic in Ayurvedic Medicines Sold via the Internet, JAMA. Ayurvedic-product contamination study; relevant to generic supply-chain risk, not branded standardized extract quality.
- Painless Thyroiditis by Withania somnifera 2024, Cureus. Case report of thyrotoxicosis/painless thyroiditis after ashwagandha use; supports thyroid-overactivity caution.
- Mishra LC et al 2000 - Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review.. Auto-resolved via strict PubMed lookup (author+year+topic match)
What does the evidence say about Ashwagandha?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
On the Outliyr Podcast, Dr. Nick Bitz noted: “I take it in gram doses every single day it really helps create balance in in my body and mind so huge fan of ashwagandha I use it every day.” (EP80).
Citations: Fatima 2024, Arumugam 2024, Alsanie 2026, Zhu 2026, Akhgarjand 2022, Bonilla 2021, Chandrasekhar 2012, Salve 2019, Langade 2019, Björnsson 2020
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Mishra 2000, LiverTox 2024, LactMed 2024
Traditional Medicine Systems
Confidence: Medium
Citations: Mishra 2000, LactMed 2024, LiverTox 2024
Holistic Evidence for Ashwagandha
The three lenses converge on ashwagandha as a stress-resilience and restoration herb, not a universal daily supplement. Modern trials support stress, anxiety, sleep, and selected performance or endocrine endpoints. Historical and traditional use point to similar fatigue, vitality, reproductive, and resilience applications. The divergence is dose and safety: modern extracts concentrate constituents, users take them continuously, and current liver, thyroid, pregnancy, and contamination data require more caution than a simple ancient-use argument provides.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Cortisol AM Baseline (pre-protocol) During | Expected Down
- TSH Baseline (pre-protocol) During | Expected Stable
- Free T4 During | Expected Stable
- Free T3 During | Expected Stable
- Testosterone Total During | Expected Up
- ALT Baseline (pre-protocol) During | Expected Stable
- AST During | Expected Stable
- GGT During | Expected Stable
- Bilirubin Total During | Expected Stable
Pulse Dimensions to Watch
- Calm During | Expected Up | Primary
- Sleep During | Expected Up | Secondary
- Drive During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Morning Grogginess Scale 1-5 | During | Expected Watch
- Perceived Stress Under Load Scale 1-5 | During | Expected Down
- Libido Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Jaundice or yellowing of eyes
- Dark urine with right upper quadrant pain
- ALT or AST above 3x baseline
- Resting HR more than 15 bpm above baseline
- New tremor, heat intolerance, or palpitations
- Worsening autoimmune thyroid symptoms
- Persistent diarrhea or GI distress
Other interventions for Stress / Resilience
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.700 − 1.258 = 1.442
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.442 / 4.00) × 5 = 6.8 / 10
